The DOI matches its Crossref record.
Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP‐1 monocyte/macrophages
Open accessAbstract
Objective: To determine whether methotrexate (MTX) can overcome the atherogenic effects of cyclooxygenase 2 (COX‐2) inhibitors and interferon‐γ (IFNγ), both of which suppress cholesterol efflux protein and promote foam cell transformation in human THP‐1 monocyte/macrophages. Methods: Message and protein levels of the reverse cholesterol transport proteins cholesterol 27‐hydroxylase and ATP‐binding cassette transporter A1 (ABCA1) in THP‐1 cells were evaluated by real‐time polymerase chain reaction and immunoblot, respectively. Expression was evaluated in cells incubated in the presence or absence of the COX‐2 inhibitor NS398 or IFNγ, with and without MTX. Foam cell transformation of lipid‐laden THP‐1 macrophages was detected with oil red O staining and light microscopy. Results: MTX increased 27‐hydroxylase message and completely blocked NS398‐induced down‐regulation of 27‐hydroxylase (mean ± SEM 112.8 ± 13.1% for NS398 plus MTX versus 71.1 ± 4.3% for NS398 alone; P < 0.01). MTX also negated COX‐2 inhibitor–mediated down‐regulation of ABCA1. The ability of MTX to reverse inhibitory effects on 27‐hydroxylase and ABCA1 was blocked by the adenosine A 2A receptor–specific antagonist ZM241385. MTX also prevented NS398 and IFNγ from increasing transformation of lipid‐laden THP‐1 macrophages into foam cells. Conclusion: This study provides evidence supporting the notion of an atheroprotective effect of MTX. Through adenosine A 2A receptor activation, MTX promotes reverse cholesterol transport and limits foam cell formation in THP‐1 macrophages. This is the first reported evidence that any commonly used medication can increase expression of antiatherogenic reverse cholesterol transport proteins and can counteract the effects of COX‐2 inhibition. Our results suggest that one mechanism by which MTX protects against cardiovascular disease in rheumatoid arthritis patients is through facilitation of cholesterol outflow from cells of the artery wall.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications
England, B. R., Thiele, G. M., Anderson, D. R., & Mikuls, T. R. (2018) · BMJ · doi:10.1136/bmj.k1036 · Cited by 609
Anti-inflammatory therapies for cardiovascular disease
Ridker, P. M., & Luscher, T. F. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu203 · Cited by 550
Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions
Raggi, P., Genest, J., Giles, J. T., Rayner, K. J., Dwivedi, G., Beanlands, R. S., & Gupta, M. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.07.014 · Cited by 433
Mechanisms of action of methotrexate
Genestier, L., Paillot, R., Quemeneur, L., Izeradjene, K., & Revillard, J.-P. (2000) · Immunopharmacology · doi:10.1016/s0162-3109(00)00189-2 · Cited by 424
Everett, B. M., Pradhan, A. D., Solomon, D. H., Paynter, N., MacFadyen, J., Zaharris, E., Gupta, M., Clearfield, M., Libby, P., Hasan, A. A. K., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.03.018 · Cited by 368
Metadata
- Authors
- Reiss, A. B., Carsons, S. E., Anwar, K., Rao, S., Edelman, S. D., Zhang, H., Fernandez, P., Cronstein, B. N., & Chan, E. S. L.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2008-11-26
- Volume
- 58
- Issue
- 12
- Pages
- 3675-3683
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2028420196
- Cited by
- 168
- References
- 0
- FWCI
- 8.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP‐1 monocyte/macrophages. https://app.cochat.ai/papers/10.1002/art.24040
- The paper
- Reiss, A. B., Carsons, S. E., Anwar, K., Rao, S., Edelman, S. D., Zhang, H., Fernandez, P., Cronstein, B. N., & Chan, E. S. L. (2008). Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP‐1 monocyte/macrophages. Arthritis & Rheumatism. https://doi.org/10.1002/art.24040
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.